Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
Clinical trial NCT02484404 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02484404
- Sponsor
- National Cancer Institute (NCI)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-06-29
- Primary completion
- 2027-10-30
- Enrollment
- 268
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.